Speciality Medicines Limited
Bookbuilding IPO · BSE
- Price band
- ₹117 - ₹124
- Lot size
- 1,000 shares
- Issue amount
- ₹29.14 cr
- Total subscription
- 2.33×
- Opens
- 20 Mar 2026
- Closes
- 24 Mar 2026
- Allotment
- 25 Mar 2026
- Listing
- 30 Mar 2026
Offer at a glance
Issue overview
- Issue size
- 23,50,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,17,000
- Fresh issue
- ₹29.14 cr
- Offer for sale
- ₹0 cr
- Registrar
- Skyline Financial Services Private Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,24,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 64,35,796
- Shares after issue
- 87,85,796
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,000 | ₹2,48,000 |
| sHNI | 3 | 3,000 | ₹3,72,000 |
| bHNI | 9 | 9,000 | ₹11,16,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 24 Mar 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 2 |
| NIB | 0 | 222 |
| RETAIL | 545 | 461 |
| HNIs(10L +) | 242 | 167 |
| HNIs (2-10L) | 121 | 55 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 0.26 | 25.06 |
| FIIs | 0 | 25.06 |
| RETAIL | 13.52 | 11.43 |
| NIB | 13.5 | 27.21 |
| HNIs 2+ | 4.5 | 2.86 |
| HNIs 10+ | 9 | 24.34 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Oct-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 9.41 | 14.1 | 7.07 | 4.74 |
| ROE | 0 | 0 | 0 | 0 |
| ROCE | 16.86 | 33.39 | 36.9 | 50.22 |
| RONW | 16.61 | 28.3 | 19.47 | 28.6 |
| PRE IPO(PE) | 0 | 9.27 | 0 | 0 |
| POST IPO(PE) | 10.49 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Speciality Medicines Limited | 9.27 | 0 | 10.00 | 47.26 | 28.42 | 14.10 |
| Remus Pharmaceuticals Limited | 10.41 | 0 | 10.00 | 434.25 | 15.02 | 65.21 |
| Trident Lifeline Limited | 27.00 | 0 | 10.00 | 56.05 | 18.23 | 10.22 |
| Mono Pharmacare Limited | 7.49 | 0 | 10.00 | 17.66 | 9.90 | 1.75 |
Company information
Company profile
Speciality Medicines Limited was incorporated in 2021 and focuses on marketing and distributing speciality pharmaceutical medicines, including expensive oral and injectable drugs used to treat serious and long-term health conditions in both Indian and international markets. The company offers many types of finished pharmaceutical products in different forms such as tablets, capsules, creams, syrups, eye drops, gels, injections, inhalers, nasal sprays, ointments, sachets, and suspensions. It operates through two main models: contract manufacturing of finished medicines for international markets and marketing and distribution of speciality medicines sourced from other manufacturers. The company has expanded globally with products registered or under registration in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia, and its distribution network covers more than 20 states in India and over 35 countries worldwide. As of March 31, 2025, one product was registered overseas and 60 products were under registration in five countries, contributing to revenue, and as of August 31, 2025, the company had 18 permanent employees working in different departments.
Strengths
- Wide Global Presence: The company operates in India as well as several international markets, helping it build a diversified revenue base and reduce dependence on a single region.
- Strong Customer Relationships: By focusing on customer needs, timely delivery, and consistent product quality, the company has developed long-term relationships and receives repeat orders from its clients.
- Reliable Quality Standards: The company follows strict quality control practices supported by ISO 9001:2015 certification and trusted third-party manufacturing facilities, ensuring consistent product quality and on-time delivery.
Risk factors
- Dependence on Third-Party Suppliers: The company relies on external suppliers for sourcing products. Any disruption, delay, or price fluctuations from these suppliers may affect product availability, pricing, and overall operations.
- Strict Quality Compliance Requirements: The company’s products must meet specific customer specifications and quality standards. Any failure to meet these requirements may result in product recalls, order cancellations, or warranty claims.
- Limited In-House R&D Capability: The company currently does not have a well-established in-house R&D team. Delays in developing this capability may impact product innovation and future growth opportunities.
Promoters
Parth B Goyani
Goyani Sumit Babubhai
Registrar & documents
Lead manager
Unicon Capital Services Private Limited
Registrar & contacts
Skyline Financial Services Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmadabad City, Ahmedabad, Gujarat, India, Ahmedabad, Gujarat, 380051
+91 22 4604 5344
[email protected]Company website ↗Frequently Asked Questions
What is Speciality Medicines IPO GMP today?
Currently, Speciality Medicines IPO Grey Market Premium (GMP) is trading around ₹0 or awaiting active buyer-seller quotes in the grey market. The issue price is set at ₹124. Track daily updates on IPO Premiums as bidding numbers unfold.
What is the lot size and minimum investment for Speciality Medicines IPO?
The minimum bid lot size for Speciality Medicines IPO is 1,000 shares. At the cut-off price of ₹124 per share, retail investors need a minimum application amount of ₹1,24,000 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).
When will Speciality Medicines IPO allotment status be announced?
The allotment status for Speciality Medicines IPO is scheduled to be finalized on 25 Mar 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Skyline Financial Services Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Speciality Medicines IPO allotment status online by PAN?
To check Speciality Medicines IPO allotment status: 1) Visit the registrar portal (Skyline Financial Services Private Limited) or the BSE IPO allotment page. 2) Select 'Speciality Medicines Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.